Overview

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Status:
RECRUITING
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
This purpose of this study is to determine if experimental treatment with BMS-986488, alone, or in combinations is safe, tolerable, and has anti-cancer activity in patients with advanced malignant tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
adagrasib
Cetuximab
Nivolumab